Secondary Hyperparathyroidism - Pipeline Review, H1 2018

  • ID: 4457552
  • Report
  • 40 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • EA Pharma Co Ltd
  • Lupin Ltd
  • OPKO Health Inc
  • Shire Plc
  • MORE
Secondary Hyperparathyroidism - Pipeline Review, H1 2018

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Secondary Hyperparathyroidism - Pipeline Review, H1 2018, provides an overview of the Secondary Hyperparathyroidism (Hormonal Disorders) pipeline landscape.

Secondary hyperparathyroidism is occurs when the parathyroid glands in neck produce too much parathyroid hormone (PTH) because calcium levels are too low. Symptoms include bone deformities, broken bones, swollen joints and chronic kidney failure. Treatment includes calcimimetic and hormone replacement therapy.

Report Highlights

The latest Pharmaceutical and Healthcare latest pipeline guide Secondary Hyperparathyroidism - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Secondary Hyperparathyroidism (Hormonal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Secondary Hyperparathyroidism (Hormonal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Secondary Hyperparathyroidism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 3, 1 and 1 respectively.

Secondary Hyperparathyroidism (Hormonal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Secondary Hyperparathyroidism (Hormonal Disorders).
  • The pipeline guide reviews pipeline therapeutics for Secondary Hyperparathyroidism (Hormonal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Secondary Hyperparathyroidism (Hormonal Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Secondary Hyperparathyroidism (Hormonal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Secondary Hyperparathyroidism (Hormonal Disorders)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Secondary Hyperparathyroidism (Hormonal Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Secondary Hyperparathyroidism (Hormonal Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • EA Pharma Co Ltd
  • Lupin Ltd
  • OPKO Health Inc
  • Shire Plc
  • MORE
Introduction

Secondary Hyperparathyroidism - Overview

Secondary Hyperparathyroidism - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Secondary Hyperparathyroidism - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Secondary Hyperparathyroidism - Companies Involved in Therapeutics Development

Deltanoid Pharmaceuticals Inc

EA Pharma Co Ltd

Lupin Ltd

Mitsubishi Tanabe Pharma Corp

OPKO Health Inc

Shire Plc

Secondary Hyperparathyroidism - Drug Profiles

AJT-240 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cinacalcet hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CTA-091 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DP-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

evocalcet - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LNP-1892 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VS-105 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Secondary Hyperparathyroidism - Dormant Projects

Secondary Hyperparathyroidism - Discontinued Products

Secondary Hyperparathyroidism - Product Development Milestones

Featured News & Press Releases

Nov 06, 2017: Kyowa Hakko Kirin Presented Results of Japan Phase III Clinical Study of Evocalcet at Kidney Week 2017 of the American Society of Nephrology

Aug 31, 2017: European Commission Approves Expanded Use Of Mimpara (Cinacalcet) For The Treatment Of Secondary Hyperparathyroidism In Children With End-Stage Renal Disease On Dialysis

Jun 23, 2017: Amgen Receives Positive CHMP Opinion To Expand Use Of Mimpara (cinacalcet) For The Treatment Of Secondary Hyperparathyroidism In Certain Children With End-Stage Renal Disease On Dialysis

Apr 27, 2017: Kyowa Hakko Kirin Submits Application for Approval of Evocalcet (KHK7580) for Secondary Hyperparathyroidism in Maintenance Dialysis Patients in Japan

Jan 31, 2017: Kyowa Hakko Kirin Announces Top-Line Results of Phase 3 Clinical Study of KHK7580 with Secondary Hyperparathyroidism in Japan

Dec 01, 2015: Kyowa Hakko Kirin Announces Commencement of Phase 3 Clinical Study of KHK7580 in Patients with Secondary Hyperparathyroidism in Japan

Oct 15, 2014: Deltanoid's DP001 (2MD) pharmaceutical demonstrated safe and effective in kidney failure patients on dialysis

Aug 29, 2014: Kyowa Hakko Kirin Announces Commencement of Phase 2b Clinical Study of KHK7580 in Patients with Secondary Hyperparathyroidism in Japan

Jun 27, 2013: Kyowa Hakko Kirin Files Application Seeking Approval For Additional Indication For Regpara Tablets 25mg And 75mg

Mar 07, 2013: Health Canada Cautions Against Use Of Amgen's Sensipar In Children

Feb 26, 2013: Amgen's Pediatric Clinical Trial Of Sensipar Suspended By FDA Following Death Of Patient

Nov 03, 2012: Amgen Announces Results From Phase III EVOLVE Trial Of Sensipar/Mimpara In Patients With Secondary Hyperparathyroidism And Chronic Kidney Disease Receiving Dialysis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Secondary Hyperparathyroidism, H1

Number of Products under Development by Companies, H1

Products under Development by Companies, H1

Number of Products by Stage and Target, H1

Number of Products by Stage and Mechanism of Action, H1

Number of Products by Stage and Route of Administration, H1

Number of Products by Stage and Molecule Type, H1

Secondary Hyperparathyroidism - Pipeline by Deltanoid Pharmaceuticals Inc, H1

Secondary Hyperparathyroidism - Pipeline by EA Pharma Co Ltd, H1

Secondary Hyperparathyroidism - Pipeline by Lupin Ltd, H1

Secondary Hyperparathyroidism - Pipeline by Mitsubishi Tanabe Pharma Corp, H1

Secondary Hyperparathyroidism - Pipeline by OPKO Health Inc, H1

Secondary Hyperparathyroidism - Pipeline by Shire Plc, H1

Secondary Hyperparathyroidism - Dormant Projects, H1

Secondary Hyperparathyroidism - Discontinued Products, H1

List of Figures

Number of Products under Development for Secondary Hyperparathyroidism, H1

Number of Products under Development by Companies, H1

Number of Products by Targets, H1

Number of Products by Stage and Targets, H1

Number of Products by Mechanism of Actions, H1

Number of Products by Stage and Mechanism of Actions, H1

Number of Products by Routes of Administration, H1

Number of Products by Stage and Routes of Administration, H1

Number of Products by Stage and Molecule Types, H
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Deltanoid Pharmaceuticals Inc
  • EA Pharma Co Ltd
  • Lupin Ltd
  • Mitsubishi Tanabe Pharma Corp
  • OPKO Health Inc
  • Shire Plc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll